5 research outputs found
Number and proportion of the three most frequent off-label indications for drugs with at least 5,000 prescriptions (year 2008, multiple counting of off-label indications per prescription).
<p>SABA: Short-acting beta-2-agonist, CGA: Cromoglicic acid, LABA: Long-acting beta-2-agonist, ICS: Inhaled corticosteroid, SAMA: Short-acting muscarinic antagonist, B2A: Beta-2-agonist, nec: not elsewhere classified.</p><p>*Exclusive missing indications.</p><p>Number and proportion of the three most frequent off-label indications for drugs with at least 5,000 prescriptions (year 2008, multiple counting of off-label indications per prescription).</p
Annual period prevalence rates per 10,000 children (≤18 years) between 2004 and 2008.
<p>Annual period prevalence rates per 10,000 children (≤18 years) between 2004 and 2008.</p
Comparison of annual period prevalence rate (PPR) of LABA-containing prescriptions in 7 European databases stratified by age and sex for the year 2008.
<p>LABA: Long-acting beta-2-agonist.</p><p>CI: Confidence interval.</p><p>*Age group: 0–19 years</p><p>Comparison of annual period prevalence rate (PPR) of LABA-containing prescriptions in 7 European databases stratified by age and sex for the year 2008.</p
Proportion of patients with “1”, “2–11”, “12–23”, and “24+” LABA containing-prescriptions in 2008, for all patients with LABA-containing prescriptions (a), asthma patients with LABA-containing prescriptions (b), COPD patients with LABA-containing prescriptions (c), and asthma and COPD patients with LABA-containing prescriptions (d) (AHC: Mondriaan–AHC, NPCRD: Mondriaan–NPCRD).
<p>Proportion of patients with “1”, “2–11”, “12–23”, and “24+” LABA containing-prescriptions in 2008, for all patients with LABA-containing prescriptions (a), asthma patients with LABA-containing prescriptions (b), COPD patients with LABA-containing prescriptions (c), and asthma and COPD patients with LABA-containing prescriptions (d) (AHC: Mondriaan–AHC, NPCRD: Mondriaan–NPCRD).</p